Neuromyelitis Optica Latest Advances

miRNA-34b overexpression alleviates neuromyelitis optica spectrum disorders by regulating the TIA-1-stress granule pathway.

Journal: Pakistan journal of pharmaceutical sciences

Published: September 08, 2026

Corrigendum to "Prevalence and incidence of neuromyelitis optica spectrum disorder in Türkiye: A nationwide epidemiologic study" [Multiple Sclerosis and Related Disorders, Volume 97 (2025): 106383].

Journal: Multiple sclerosis and related disorders

Published: September 07, 2026

Recommendations for the diagnosis and treatment of optic neuromyelitis in children and adolescents

Journal: Medicina

Published: August 27, 2026

De-Escalating and Discontinuing Immunotherapies in Patients With NMOSD and MOGAD.

Journal: Neurology

Published: August 26, 2026

Antibodies against MLC1 found in patients with NMOSD-like disease mediate astrocytopathy in rodent models.

Journal: Science translational medicine

Published: August 26, 2026

2,6-diaminopurine enhances Aqp4 stop codon readthrough and AQP4 perivascular localization in the brain.

Journal: bioRxiv : the preprint server for biology

Published: August 20, 2026

Use of Fluid Biomarkers in NMOSD and MOGAD: Clinical and Research Applications.

Journal: Neurology(R) neuroimmunology & neuroinflammation

Published: August 11, 2026

Role of complement and complement-targeted therapeutics in neurological diseases.

Journal: Nature reviews. Neurology

Published: August 11, 2026

Complement C3 inhibitory peptide AMY-101 ameliorates brain injury in a mouse model of NMOSD.

Journal: Annals of medicine

Published: August 08, 2026

Coexistence of Neuromyelitis Optica Spectrum Disorder and Proliferative Lupus Nephritis: A Rare Case Report.

Journal: The Journal of the Association of Physicians of India

Published: August 03, 2026

Expanding the Spectrum: Isolated Acute Diencephalitis as the Initial Manifestation of Neuromyelitis Optica Spectrum Disorder.

Journal: The Journal of the Association of Physicians of India

Published: August 03, 2026

Movement-Provoked Paroxysmal Neuralgia Following Longitudinally Extensive Transverse Myelitis in Neuromyelitis Optica Spectrum Disorder: A Presumed Ephaptic Spinal Cord Phenomenon.

Journal: Cureus

Published: August 02, 2026

Neuromyelitis Optica Latest Advances

Find the Latest Research About Neuromyelitis Optica

miRNA-34b overexpression alleviates neuromyelitis optica spectrum disorders by regulating the TIA-1-stress granule pathway.

miRNA-34b overexpression alleviates neuromyelitis optica spectrum disorders by regulating the TIA-1-stress granule pathway.

Corrigendum to "Prevalence and incidence of neuromyelitis optica spectrum disorder in Türkiye: A nationwide epidemiologic study" [Multiple Sclerosis and Related Disorders, Volume 97 (2025): 106383].

Corrigendum to "Prevalence and incidence of neuromyelitis optica spectrum disorder in Türkiye: A nationwide epidemiologic study" [Multiple Sclerosis and Related Disorders, Volume 97 (2025): 106383].

Recommendations for the diagnosis and treatment of optic neuromyelitis in children and adolescents

Recommendations for the diagnosis and treatment of optic neuromyelitis in children and adolescents

De-Escalating and Discontinuing Immunotherapies in Patients With NMOSD and MOGAD.

De-Escalating and Discontinuing Immunotherapies in Patients With NMOSD and MOGAD.

Antibodies against MLC1 found in patients with NMOSD-like disease mediate astrocytopathy in rodent models.

Antibodies against MLC1 found in patients with NMOSD-like disease mediate astrocytopathy in rodent models.

2,6-diaminopurine enhances Aqp4 stop codon readthrough and AQP4 perivascular localization in the brain.

2,6-diaminopurine enhances Aqp4 stop codon readthrough and AQP4 perivascular localization in the brain.

Use of Fluid Biomarkers in NMOSD and MOGAD: Clinical and Research Applications.

Use of Fluid Biomarkers in NMOSD and MOGAD: Clinical and Research Applications.

Role of complement and complement-targeted therapeutics in neurological diseases.

Role of complement and complement-targeted therapeutics in neurological diseases.

Complement C3 inhibitory peptide AMY-101 ameliorates brain injury in a mouse model of NMOSD.

Complement C3 inhibitory peptide AMY-101 ameliorates brain injury in a mouse model of NMOSD.

Coexistence of Neuromyelitis Optica Spectrum Disorder and Proliferative Lupus Nephritis: A Rare Case Report.

Coexistence of Neuromyelitis Optica Spectrum Disorder and Proliferative Lupus Nephritis: A Rare Case Report.

Expanding the Spectrum: Isolated Acute Diencephalitis as the Initial Manifestation of Neuromyelitis Optica Spectrum Disorder.

Expanding the Spectrum: Isolated Acute Diencephalitis as the Initial Manifestation of Neuromyelitis Optica Spectrum Disorder.

Movement-Provoked Paroxysmal Neuralgia Following Longitudinally Extensive Transverse Myelitis in Neuromyelitis Optica Spectrum Disorder: A Presumed Ephaptic Spinal Cord Phenomenon.

Movement-Provoked Paroxysmal Neuralgia Following Longitudinally Extensive Transverse Myelitis in Neuromyelitis Optica Spectrum Disorder: A Presumed Ephaptic Spinal Cord Phenomenon.